Presbia Announces the Appointment of Jake Vander Zanden as Chief Commercial
IRVINE, Calif. -- February 19, 2013
Presbia, a medical device company and leader in near vision restoration,
announced today the appointment of Jake Vander Zanden as Chief Commercial
Officer. Bringing more than 25 years of experience in the healthcare industry,
Mr. Vander Zanden will be responsible for expanding the commercial growth of
the Presbia Flexivue Microlens™, the company’s implantable corneal inlay
solution for presbyopia, the age-related loss of near vision.
“Jake’s extensive experience in the ophthalmology space will be extremely
valuable to Presbia as we continue to ramp up our efforts to grow the
commercial availability of the Presbia Flexivue Microlens™ outside of the
United States,” said Zohar Loshitzer, Chief Executive Officer of Presbia. “By
adding top talent and resources to these efforts, we hope to be able to
accelerate market availability of our innovative solution for the correction
of near vision loss to an even greater number of patients.”
Mr. Vander Zanden has served in top positions at major global corporations
focused on ophthalmology. Most recently, he served as President of the
Americas at Hoya Surgical Optics, a manufacturer of ophthalmic intraocular
lenses (IOLs) based in Singapore. He has also served as Corporate Vice
President, SVP & General Manager at Lumenis, Inc., a manufacturer of
ophthalmic lasers, and as Vice President and General Manager, Global Pain
Management at Medtronic Neurological, and has held senior leadership roles in
multiple international assignments with Allergan, Inc., a multi-specialty
healthcare company focused on pharmaceuticals, biologics, medical devices and
over-the-counter consumer products. He serves on the Board of Directors of
Prevent Blindness America, and the Board of Advisors for the Sand Hill
“The Presbia Flexivue Microlens™ offers a truly innovative solution for
presbyopia, a condition that affects so many people around the world, and I am
excited to join the Presbia team and lead the efforts to broaden its
commercial availability,” said Mr. Vander Zanden.
Presbia submitted its Investigational Device Exemption request with U.S. Food
& Drug Administration in September 2012 for the Presbia Flexivue Microlens™.
The lens received the CE Mark in 2009, and today it is widely available
commercially in Europe, Latin America, the Middle East and Asia.
ABOUT PRESBIA AND THE PRESBIA FLEXIVUE MICROLENS
Presbia is a leading ophthalmic-device company focused on the development of
solutions for presbyopia, the age-related loss of the ability to read or focus
on near objects. Chief among these approaches is the Presbia Flexivue
Microlens™, a 3mm-diameter lens that is implanted in the corneal stroma of the
patient’s non-dominant eye using femtosecond laser technology. The procedure
requires no general anesthesia, and the patient’s visual recovery typically
takes only a couple of days. Since the Presbia Flexivue Microlens™ solution
utilizes standard equipment and requires minimal additional training, the
procedure requires no significant capital investment by the surgeon’s
Further information is available at www.presbia.com.
Note: Not Available for Sale in the United States.
Sarah Troutt, +1-212-397-1030
Press spacebar to pause and continue. Press esc to stop.